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ABSTRACT 
 
Head and neck cancer is one of the ten most common cancers in the World constituting 15% of all malignancies. 
Head & Neck cancers rank 3rd in developing countries.In the prementioned context the current study is aimed at 
assessing patient compliance to concurrent chemo- radiation and also about the various factors influencing the 
outcome in the cases of head and neck cancers attending to Department of Radiotherapy, Government Medical 
College and General Hospital, Anantapuramu. Of a total number of 135 cases of head and neck tumours were 
treated with Radiation during the aforementioned period, 70 cases of locally advanced disease that are treated with 
Radical Radiation and concurrent chemotherapy were included in the study. In our study, we noticed complete 
response in 60 % of the patients. Response was significantly influenced by the site of the primary. Patients with 
primary in Nasopharynx and Larynx had better response, 80 % and 70 % respectively compared to.   Tumor 
response was better in patients who completed treatment without breaks and with good performance status. 
Concurrent chemoradiation results in grade III reactions which have to be managed aggressively. Nutrition of the 
patient should be maintained with nasogastric or PEG tubes if needed along with parenteral nutrition. Weekly blood 
counts should be checked. Antifungals and antibiotics should be used whenever needed. Patients need counselling 
regarding diet and high protein diet should be advised.  
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Introduction 
 
Head and neck cancer is one of the ten most common 
cancers in the World constituting 15% of all 
malignancies. Head & Neck cancers rank 3rd in 
developing countries.The age-adjusted rates of head 
and neck cancers are highest in countries like France, 
India, Brazil, and USA (blacks). Among females the 
age-adjusted rates of India are the highest in the world 
[1-2].  Its incidence is high in Central & South East 
Asian Countries and is linked mainly to tobacco 
chewing and tobacco smoking.  
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However, there is an overall reduction in the incidence 
of head and neck cancers in both urban and rural 
community. This is more pronounced in the urban 
community, probably due to the reduction in the use of 
tobacco in that population [11]. 
 Radiotherapy is one of the lone long standing standard 
non-surgical therapy for locally advanced disease.  
Optimizing locoregional control disease-free and 
overall survival remains a challenging goal in 
management of Head & Neck Cancers.  Reducing 
toxicity and organ preservation are laudable pursuits, 
but the prime concern will always remain optimizing 
the cure.  Many fractionationed regimens conventional 
once daily treatments, hyper fractionation regimens, 
concomitant boost and accelerated fractionation have 
been used.  These emerging newer strategies lead to a 
10% to 15% improvement in locoregional control 
relative to once daily treatment scheme.  Even the most 
effective RT regimens result in local control rates of 
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50% to 70% and disease-free survival rates of 30% to 
40%.  This led to management of cancers by the 
combination of chemotherapy with Radiotherapy [3]. 
Radiotherapy and concurrent chemotherapy is more 
attractive strategy because some chemotherapeutic 
agents may both radio sensitise cells and provide 
additive toxicity.  This has been demonstrated to 
produce a small but significant survival advantage. 
However, concurrent use of chemotherapy and 
radiotherapy is known to increase toxicity which may 
compromise radiation dose or may prolong the 
treatment time that may ultimately affect the potential 
gains of combined modality.  In the prementioned 
context the current study is aimed at assessing patient 
compliance to concurrent chemo- radiation and also 
about the various factors influencing the outcome in 
the cases of head and neck cancers attending to 
Department of Radiotherapy, Government Medical 
College and General Hospital, Anantapuramu. 
 
Materials and methods 
 
The current prospective study was carried out from 
January 2014 and May 2015 at Department of 
Radiotherapy and Department of Pathology, 
Government Medical College and General Hospital, 
Anantapuramu after obtaining clearance from 
Institutional Ethics Committee and consent from all the 
patients who are included in the study. Of a total 
number of 135 cases of head and neck tumours were 
treated with Radiation during the aforementioned 
period, 70 cases of locally advanced disease that are 
treated with Radical Radiation and concurrent 
chemotherapy were included in the study.  All the 
subjects were histologically proven to have squamous 
cell carcinoma.  AJCC cancer staging manual 
(7thedition)[4] was used for staging. Complete 
haematological and biochemical profiles were done 
before starting the treatment.  CT and MRI are done 
whenever necessary.  Toxicity was documented using 
NCIC common toxicity criteria [5].  Radiotherapy was 
given with Cobalt 60 machine (Theratron 780C). Dose 
was 63 to 72 Gy in 35 to 40 fractions for definitive 
concurrent chemo radiotherapy with 180 cGy per 
fraction, five days per week. Patient is treated in supine 
position. Immobilization with thermoplastic mask was 
done.     EBRT was performed through two lateral 
opposing portals or two lateral portals and an anterior 
neck field.  Spinal cord was shielded after 40 Gy and 
posterior neck was treated with appropriate tangential 
fields sparing spinal cord. Check films are done to 
verify field borders. Chemotherapy consisted of 
Cisplatin, administered weekly at a dose of 40 mg/m2 
with a total single dose of up to 60 mg. Cisplatin dose 
was adjusted based on 24-hour creatinine clearance, 
body surface area and performance status.  Cisplatin 
was administered with normal saline over two hours 
with appropriate pre-andpost-hydration.  Antiemetic 
therapy with ondansetron and steroids were given 
routinely on the day of Chemotherapy.Complete 
haematological and biochemical profiles were done 
before starting chemotherapy.  Urinary creatinine 
clearance of at least 50 ml/min was required; otherwise 
dose of Cisplatin was adjusted.  Haemoglobin, white 
blood cell count and platelet counts were assayed 
before each Cisplatin administration.  Chemotherapy 
was given only when counts were normal.  Colony 
stimulating factors were not used. Patients were 
evaluated every week for toxicity during treatment 
period.  Mucositis, skin reaction and haematological 
toxicity were assessed.  If needed, ryles tube placement 
was done for nutrition.  Routine mouth gargles and 
dental care was taken.  Antibiotics and antifungals 
were used whenever needed. Anaesthetic gels and 
steroids were used. Packed cell transfusions were given 
whenever needed.    
 
Observations 
 
Of a total 135 cases of head and neck cancers treated 
during the study period, 82 cases were treated with 
radical radiotherapy and chemotherapy. Of these 75 
cases 70 cases were treated with radiotherapy and 
concurrent weekly Cisplatin, two were treated with 
concurrent Taxol and ten were treated with concurrent 
Cisplatin and 5FU. The 70 cases treated with radical 
radiotherapy and concurrent weekly Cisplatin are taken 
into the study. In the remaining cases seven were 
treated with only radical radiotherapy, eight cases were 
treated with palliative radiotherapy, three cases did not 
receive any treatment, four cases discontinued 
treatment after one week and 29 cases were treated 
postoperatively. Of the seventy cases that are managed 
with radical radiotherapy and weekly dose of Cisplatin, 
the commonest site was oral cavity constituting nearly 
half of the total cases, tongue being commonest of all. 
The median age was 56 years. Around 90% of the 
cases had nodal disease and 35% of cases had T4 
disease. 10 patients had performance status below 70%. 
Cisplatin dose ranged from 30 to 60 mg. Dose was 
adjusted according to creatinine clearance body surface 
area and performance status. The General Features of 
observations are presented in Tale No.1 below and 
Cancer staging and particulars as to chemotherapy, 
radiotherapy, overall treatment times and treatment 
breaks are depicted in Table-2. 
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                                                Table 1: Statistics as to age, sex and site of cancer 
Characteristic Value 
Age:   
Range 18-78 
Median 56 
Sex:  
Male 48 
Female 22 
Site:  
Oral cavity 23 
Oropharynx 11 
Hypopharynx 20 
Nasopharynx 5 
Larynx 8 
Unknown 3 
   
 
Table 2: Distribution of cases as to cancer staging and management strategies 
Characteristic value 
T stage:   
Tx 3 
T2 10 
T3 33 
T4 24 
N stage:   
N0 5 
N1 21 
N2 27 
N3 17 
Chemotherapy:   
Six cycles 37 
Five cycles 22 
Four cycles 10 
Three cycles 1 
Radiotherapy:   
65 – 75 Gy 66 
Discontinued 4 
Overall treatment time:   
Range 42 – 70 days 
Median 56 days 
Treatment breaks:   
Without break 43 
With break 23 
 
Toxicity: Skin, mucous membrane, pharynx 
(dysphagia), salivary gland, gastrointestinal and 
hematological toxicity were graded according to NCIC 
Common Toxicity Criteria. 
Hematological Toxicity:Hematological toxicity was 
mild. Grade I leucopenia was seen in 10 patients. 
Chemotherapy was skipped for that week though 
radiation was not stopped. No grade II or III leucopenia 
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were noted.Anemia of grade I was noted in 11 patients, 
though treatment was not interrupted. Grade II anemia 
was seen in 5 patients and grade III in three patients. 
Blood transfusions (packed cells) were given for all 
patients with anaemia. No grade IV anaemia was 
noted.No patient developed thrombocytopenia. 
GI Toxicity:Gastrointestinal toxicity was mild. 35 
patients had grade I nausea and no grade II or III 
nausea seen. Grade-I vomiting was noted in 51 patients 
and grade II vomiting in 12 patients. No grade III or IV 
vomiting noted. All the patients were treated with 
antiemetics and steroids prior to chemotherapy. 
Skin Toxicity:Grade I dermatitis is noted in 15 
patients. Grade II skin reaction is seen in 45 patients. 
Grade III reaction seen in 10 patients. No grade IV 
reaction is seen. Treatment was interrupted in patients 
with grade III dermatitis. Supportive care was given 
with Gentian violet paint and steroid ointments. 
Antibiotics were added whenever needed. 
Mucositis: Grade I mucositis was seen in nine patients. 
Grade II Mucositis is noted in 46 patients and grade III 
Mucositis in 15 patients. Treatment was interrupted in 
patients with grade III mucositis. Supportive care is 
given with mouth gargles and anaesthetic gels. 
Antibiotics were given routinely in patients with grade 
III mucositis. 36 patients developed oral candidiasis 
and were treated with candid mouth paints and oral 
fluconazole. No grade IV Mucositis is noted. 
Dysphagia (pharynx ):Grade I dysphagia was seen in 
16 patients. Grade II dysphagia was noted in 31 
patients and grade III in 23 patients. Ryles tube 
placement was done in these patients with grade III 
reaction to maintain nutrition. Ten patients had Ryles 
tube placed from the beginning of treatment. 
Salivary Gland Toxicity: Grade I reaction (thickened 
sputum) was seen in 31 patients and grade II reaction 
in 39 patients. No grade IV reaction was noted 
Treatment was interrupted in 23 patients (33 %). 
Treatment break was due to grade III mucositis or 
dysphagia or skin reaction. One week to ten days rest 
was given. In one patient the gap was for three weeks. 
One patient died on treatment due to aspiration 
pneumonitis and four patients discontinued treatment 
after 40 Gy. The overall treatment time ranged from 
seven weeks to ten weeks with a median of eight 
weeks. Patients with good performance status and good 
nutritional status tolerated the treatment well. 
chemotherapy dose was reduced after three weeks in 
seven patients due to grade III reaction. Chemotherapy 
was discontinued in six patients after four cycles due to 
grade III reaction. No renal toxicity was found. One 
patient developed ototoxicity in the form of loss of 
hearing after one month of treatment completion.  
Complete tumour response was seen in 42 patients 
clinically immediately after completion of treatment 
and 33 patients had partial response. At the end of the 
treatment, response was assessed only clinically. At the 
first follow-up, done after one month of completion of 
treatment, response and reactions were reassessed. 
Response was assessed clinically and with cytology in 
tumours of oral cavity and with endoscopies in cases of 
oropharynx,hypopharynx and larynx. CT scan and 
barium swallow were done whenever needed. At first 
follow up 60 % of the patients showed complete 
response and 22 % of the patients showed partial 
response. Four patients (5.7 %) discontinued treatment. 
One patient (1.4 %) expired during treatment. The 
remaining 11 % of the patients had progressive disease.  
  Response rates depended on site, stage (tumour 
burden) and performance status.  Patients with primary 
in the tongue had poorer response rates and patients 
with primary in larynx had better response. 
Performance status at the beginning of treatment also 
mattered. Patients with good performance status were 
able to complete treatment without breaks and had 
good response. In our study, we had 23 cases of 
primary in oral cavity. Of these, 12 patients showed 
complete response (52%). Of 11 patients with 
carcinoma oropharynx, 5 patients had complete 
response (45.5%). 14 of 20 patients (70%) with 
primary in hypopharynx had complete response. We 
had 5 cases of Nasopharynx, of these 4 patients had 
complete response (80%) and 6 cases out of 8 with 
primary in larynx had complete response (75%). 
 
Discussion 
 
The yield of radiotherapy alone in advanced squamous 
cell carcinoma of head and neck, decreases with 
increasing stage of the disease. For some advanced 
lesions, combination of surgery and radiation are 
feasible, but a significant percentage of these tumors 
are not surgically resect able and the alternative of 
using initial radical radiotherapy and chemotherapy, 
reserving surgery for salvage seems to show almost 
equal results as combined radiation and surgery. 
 The concomitant use of chemotherapy and 
radiotherapy has been most promising approach to 
combine radiation and chemotherapy, compared to 
neoadjuvant or adjuvant chemotherapy. A variety of 
chemotherapeutic drugs have been used concurrently 
with radiotherapy as monotherapy or combination 
therapy. 
 Several groups have evaluated Cisplatin and 5-FU in 
combination with radiation and shown improved 
control but at the cost of increased toxicity. More 
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recently, Paclitaxel has been investigated with radiation 
treatment, both as a single agent and in combination 
with Cisplatin. Results are promising, but need phase 
III trial evaluation and toxicity is the main concern. In 
the concurrent set up single agent chemotherapy based 
on platinum compound is the treatment of choice. 
The dose and delivery schedules of Cisplatin have 
ranged from intermittent higher dose (100 mg/m2) 
every three weeks to low dose (6 mg/m2) daily 
administration. At our institute we use Cisplatin 40 
mg/m2 weekly concurrently with radiotherapy. 
Cisplatin dose is adjusted according to creatinine 
clearance, body surface area and performance status. 
 Serin et al[6] , used weekly Cisplatin 30 mg/m2, 
reported better response rates and 14% of grade III 
toxicity.Porceddu et al [7], used weekly Cisplatin 35 
mg/m2 following surgery in 47 patients. They reported 
40% grade III mucositis.Glaser et al [8], used weekly 
Cisplatin 35 mg/m2 and 87% of patients could 
complete treatment without breaks and 13% had grade 
III mucositis. 
 Concurrent chemotherapy with three weekly Cisplatin 
100mg/m2 was used in a quite a number of trials. 
RTOG 9501and EORTC 22931 trials [9] showed 55% 
and 41% mucositis.In our study we have noticed 61 % 
grade II and 13 % grade III skin reaction. Grade II 
mucositis was seen in 58 % and grade III in 21 % of 
patients. Grade II dysphagia was seen in 44 % and 
grade III in 32 % of patients. Overall, we have noticed 
22% of grade III reaction and 33% of treatment breaks. 
Response rates were 60%.A study conducted at 
Amritha Institute of Medical Sciences, Kochi [10], 
compared acute toxicities of two chemotherapy 
schedules – weekly Cisplatin (40 mg/m2) and three 
weekly Cisplatin (100 mg/m2) administered on week 1, 
4 and 7. Results showed 8% grade III skin reaction and 
4% grade III mucositis in three weekly regimens. 16% 
grade III skin reaction and 28% grade III mucositis in 
weekly regimen. 
The results of our study were comparable to the other 
studies. We noticed 22 % grade III reaction. In RTOG 
9501 trial, where three weekly Cisplatin (100 mg/ m2) 
was given, 55 % grade III toxicity was reported. Trials 
using weekly Cisplatin showed less toxicity. Serin etal 
reported only 14 % grade III toxicity. In this study, 
dose of Cisplatin was 30 mg/ m2. it appears that dose 
less than 40 mg/m2 is better tolerated. 
 In our study, we noticed complete response in 60 % of 
the patients. Response was significantly influenced by 
the site of the primary. Patients with primary in 
Nasopharynx and Larynx had better response, 80 % 
and 70 % respectively compared to.Tumor response 
was better in patients who completed treatment without 
breaks and with good performance status. 
  Concurrent chemoradiation results in grade III 
reactions which have to be managed aggressively. 
Nutrition of the patient should be maintained with 
nasogastric or PEG tubes if needed along with 
parenteral nutrition. Weekly blood counts should be 
checked. Antifungals and antibiotics should be used 
whenever needed. Patients need counselling regarding 
diet and high protein diet should be advised.        
 
Reference 
 
1. Ferlay J, Héry C, Autier P, Sankaranarayanan R. 
Global burden of breast cancer. InBreast cancer 
epidemiology 2010 (pp. 1-19). Springer New 
York. 
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global 
cancer statistics, 2002. CA: a cancer journal for 
clinicians. 2005;55(2):74-108. 
3. Bartelink H, Roelofsen F, Eschwege F, Rougier P, 
Bosset JF, Gonzalez DG, Peiffert D, Van 
Glabbeke M, Pierart M. Concomitant radiotherapy 
and chemotherapy is superior to radiotherapy 
alone in the treatment of locally advanced anal 
cancer: results of a phase III randomized trial of 
the European Organization for Research and 
Treatment of Cancer Radiotherapy and 
Gastrointestinal Cooperative Groups. Journal of 
clinical oncology. 1997;15(5):2040-9. 
4. Edge SB, Compton CC. The American Joint 
Committee on Cancer: the 7th edition of the AJCC 
cancer staging manual and the future of TNM. 
Annals of surgical oncology. 2010;17(6):1471-4.0 
5. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu 
K, Gunderson L, McCormick B, Morris M, Rich 
T, Shipley W. Common toxicity criteria: version 
2.0. an improved reference for grading the acute 
effects of cancer treatment: impact on 
radiotherapy. International Journal of Radiation 
Oncology* Biology* Physics. 2000;47(1):13-47. 
6. Serin M, Erkal HS, Cakmak A. Radiation therapy, 
cisplatin and hyperthermia in combination in 
management of patients with recurrent carcinomas 
of the head and neck with metastatic cervical 
lymph nodes. International journal of 
hyperthermia. 1999;15(5):371-81. 
7. Porceddu SV, Sidhom M, Foote M, Burmeister E, 
Stoneley A, El Hawwari B, Milross C, Kenny L, 
Poulsen M, Coman WB. Predicting regional 
control based on pretreatment nodal size in 
squamous cell carcinoma of the head and neck 
treated with chemoradiotherapy: A clinican’s 
 
Asian Pac. J. Health Sci., 2016; 3(1):188-193                                           e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
 Prasanthi J, Sivasankara   ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016; 3(1):188-193                              193 
www.apjhs.com       
 
guide. Journal of medical imaging and radiation 
oncology. 2008 ;52(5):491-6. 
8. Glaser MG, Leslie MD, O'Reilly SM, Cheesman 
AD, Newlands ES. Weekly cisplatinum 
concomitant with radical radiotherapy in the 
treatment of advanced head and neck cancer. 
Clinical Oncology. 1993;5(5):286-9. 
9. Bernier J, Cooper JS, Pajak TF, Van Glabbeke M, 
Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, 
Jassem J, Ang KK, Lefèbvre JL. Defining risk 
levels in locally advanced head and neck cancers: 
a comparative analysis of concurrent postoperative 
radiation plus chemotherapy trials of the EORTC 
(# 22931) and RTOG (# 9501). Head & neck. 
2005;27(10):843-50. 
10. Geeta SN, Padmanabhan TK, Samuel J, Pavithran 
K, Iyer S, Kuriakose MA. Comparison of acute 
toxicities of two chemotherapy schedules for head 
and neck cancers. Journal of cancer research and 
therapeutics. 2006 ;2(3):100. 
11. Elango JK, Gangadharan P, Sumithra S, Kuriakose 
MA. Trends of head and neck cancers in urban and 
rural India. Asian Pacific Journal of Cancer 
Prevention. 2006;7(1):108. 
 
 
 
 
Source of Support: Nil                              
Conflict of Interest: None  
 
